• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Guard Therapeutics

1.60 SEK

+3.77 %

Less than 1K followers

GUARD

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.77 %
+30.56 %
+3.77 %
+8.71 %
+9.08 %
-91.00 %
-72.23 %
-97.73 %
-99.91 %

Guard Therapeutics is engaged in the development of drugs in the field of oxidative stress. The company focuses primarily on research, development and commercialization of drugs that aim to prevent the onset and complications of acute kidney injury. The drug has been shown in preclinical studies to protect exposed tissue and support regenerative processes. The company is headquartered in Lund.

Read more
Market cap
32.23M SEK
Turnover
296.44K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/7
2026

Extraordinary general meeting '26

20/8
2026

Interim report Q2'26

12/11
2026

Interim report Q3'26

Press release6 hours ago

Guard Therapeutics initierar transaktionsprocess avseende GTX-plattformen

Guard Therapeutics
Press release6 hours ago

Guard Therapeutics Initiates Transaction Process for the GTX Platform

Guard Therapeutics
Regulatory press releaseyesterday

Kallelse till extra bolagsstämma i Guard Therapeutics International AB (publ)

Guard Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press releaseyesterday

Guard Therapeutics har ingått villkorat avtal om omvänt förvärv av Disruptive Pharma

Guard Therapeutics
Regulatory press releaseyesterday

Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma

Guard Therapeutics
Regulatory press release5/28/2026, 10:30 AM

Kommuniké från årsstämma i Guard Therapeutics International AB (publ) den 28 maj 2026

Guard Therapeutics
Regulatory press release5/11/2026, 6:30 AM

Guard Therapeutics offentliggör delårsrapport för januari–mars 2026

Guard Therapeutics
Regulatory press release4/27/2026, 6:00 AM

Kallelse till årsstämma i Guard Therapeutics International AB (publ)

Guard Therapeutics
Regulatory press release4/21/2026, 1:20 PM

Guard Therapeutics publicerar årsredovisning 2025

Guard Therapeutics
Regulatory press release4/9/2026, 3:10 PM

Guard Therapeutics informerar om observationsstatus på Nasdaq First North Growth Market

Guard Therapeutics
Regulatory press release4/9/2026, 3:10 PM

Guard Therapeutics provides information regarding observation status on Nasdaq First North Growth Market

Guard Therapeutics
Press release3/31/2026, 1:45 PM

Guard Therapeutics lämnar uppdatering avseende strategisk översyn

Guard Therapeutics
Press release3/31/2026, 1:45 PM

Guard Therapeutics provides update on strategic review

Guard Therapeutics
Regulatory press release2/20/2026, 7:30 AM

Guard Therapeutics offentliggör bokslutskommuniké för 2025

Guard Therapeutics
Regulatory press release2/5/2026, 3:45 PM

Guard Therapeutics meddelar idag förändringar i bolagets ledningsgrupp

Guard Therapeutics
Regulatory press release2/5/2026, 3:45 PM

Guard Therapeutics Announces Changes to the Company’s Management Team

Guard Therapeutics
Press release2/5/2026, 3:35 PM

Guard Therapeutics ger statusuppdatering avseende pågående strategisk översyn

Guard Therapeutics
Press release2/5/2026, 3:35 PM

Guard Therapeutics Provides Status Update Regarding Ongoing Strategic Review

Guard Therapeutics
Press release1/15/2026, 3:55 PM

Guard Therapeutics blir partner i europeiskt forskningskonsortium för Alports syndrom

Guard Therapeutics
Press release1/15/2026, 3:55 PM

Guard Therapeutics Partners in EU Consortium For Alport Syndrome

Guard Therapeutics